Stockscreener 앱 받기
1.50
2.74%
0.04
시간 외 거래:
1.50
전일 마감가:
$1.46
열려 있는:
$1.42
하루 거래량:
43,461
Relative Volume:
0.16
시가총액:
$17.36M
수익:
$996.00K
순이익/손실:
$-6.09M
주가수익비율:
-2.8302
EPS:
-0.53
순현금흐름:
$-9.76M
1주 성능:
+2.74%
1개월 성능:
+51.52%
6개월 성능:
+7.14%
1년 성능:
-29.25%
1일 변동 폭
$1.42
$1.52
1주일 범위
$1.40
$1.54
52주 변동 폭
$0.70
$2.44
Therapeuticsmd Inc Stock (TXMD) Company Profile
명칭
Therapeuticsmd Inc
전화
561-961-1900
주소
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
TXMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.50 | 16.90M | 996.00K | -6.09M | -9.76M | -0.53 |
|
HLN
Haleon Plc Adr
|
10.80 | 48.39B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
163.04 | 70.91B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.85 | 3.54M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.11 | 45.20B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.94 | 19.42B | 16.54B | -1.64B | 749.00M | -1.45 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-08-07 | 다운그레이드 | Jefferies | Hold → Underperform |
| 2020-05-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-12-02 | 개시 | Guggenheim | Buy |
| 2019-10-17 | 개시 | H.C. Wainwright | Buy |
| 2019-04-30 | 재개 | Noble Capital Markets | Outperform |
| 2018-06-15 | 개시 | JP Morgan | Overweight |
| 2017-09-08 | 개시 | Morgan Stanley | Equal-Weight |
| 2017-07-11 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2017-05-09 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2016-11-22 | 재개 | Jefferies | Buy |
| 2016-11-22 | 개시 | Oppenheimer | Outperform |
| 2016-11-07 | 재개 | Guggenheim | Buy |
| 2016-04-04 | 개시 | Goldman | Buy |
| 2015-12-08 | 재확인 | Jefferies | Buy |
| 2015-12-08 | 재확인 | Stifel | Buy |
| 2015-09-21 | 재확인 | Jefferies | Buy |
| 2015-06-09 | 개시 | Guggenheim | Buy |
| 2014-07-08 | 개시 | FBR Capital | Outperform |
| 2014-04-17 | 재확인 | Noble Financial | Buy |
| 2014-01-28 | 재확인 | Noble Financial | Buy |
모두보기
Therapeuticsmd Inc 주식(TXMD)의 최신 뉴스
TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com - Defense World
TherapeuticsMD Reports Improved Q1 2025 Results - TipRanks
TherapeuticsMD Announces First Quarter 2025 Financial Results | - GuruFocus
TherapeuticsMD: Q1 Earnings Snapshot - CT Insider
TherapeuticsMD Announces First Quarter 2025 Financial Results - BioSpace
TherapeuticsMD Inc Reports Q1 2025 Results: EPS at -$0.06, Reven - GuruFocus
TherapeuticsMD Reports Q1 2025 Financial Results - TipRanks
TherapeuticsMD Q1 Operating Expenses USD 1.264 Million - marketscreener.com
TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com - Defense World
Today's Dead Cat Bounce Stock: TherapeuticsMD (TXMD) - TheStreet
StockNews.com Begins Coverage on TherapeuticsMD (NASDAQ:TXMD) - Defense World
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
Press Release Distribution & PR Platform - ACCESS Newswire
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD (NASDAQ:TXMD) Earns Hold Rating from Analysts at StockNews.com - Defense World
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock By Investing.com - Investing.com Canada
TherapeuticsMD director Tommy Thompson acquires $325 in stock - Investing.com Australia
TherapeuticsMD director Tommy Thompson acquires $325 in stock By Investing.com - Investing.com Canada
TherapeuticsMD CEO Marlan Walker acquires $489 in common stock - Investing.com
TherapeuticsMD CEO Marlan Walker buys $489 in common stock By Investing.com - Investing.com South Africa
TherapeuticsMD CEO Marlan Walker buys $489 in common stock - Investing.com
INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
DEADLINE TODAY: Lundin Law PC Announces a Securities Class Action Lawsuit against TherapeuticsMD, Inc. and Reminds Investors with Losses to Contact the Firm - ACCESS Newswire
Mayne Pharma Faces Legal Challenge from TherapeuticsMD - TipRanks
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock - Investing.com Australia
TherapeuticsMD CEO Marlan Walker buys $1,994 in stock By Investing.com - Investing.com India
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsmdFiles Lawsuit Against Mayne Pharma For Breach Of Contract - marketscreener.com
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Therapeuticsmd Inc (TXMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Therapeuticsmd Inc 주식 (TXMD) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Walker Marlan D | Chief Executive Officer |
Apr 14 '25 |
Buy |
1.00 |
490 |
489 |
73,639 |
| Walker Marlan D | Chief Executive Officer |
Apr 10 '25 |
Buy |
0.86 |
1,167 |
1,000 |
73,149 |
| Walker Marlan D | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.87 |
1,136 |
994 |
71,982 |
| Collins Cooper C. | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
60,516 |
| Naughton Gail K | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
8,500 |
| Thompson Tommy G | Director |
Feb 18 '25 |
Option Exercise |
0.00 |
8,500 |
0 |
14,454 |
| Walker Marlan D | Chief Executive Officer |
Feb 18 '25 |
Option Exercise |
0.00 |
8,281 |
0 |
70,846 |
| Collins Cooper C. | Director |
Aug 22 '24 |
Buy |
1.73 |
4,094 |
7,099 |
52,016 |
| Collins Cooper C. | Director |
Aug 21 '24 |
Buy |
1.70 |
1,200 |
2,039 |
47,922 |
0.57%
자본화:
|
볼륨(24시간):